Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 30;13(2):22.
doi: 10.3390/ph13020022.

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology

Christine Rangger  1 , Roland Haubner  1
Affiliations
Review

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology

Christine Rangger et al. Pharmaceuticals (Basel). .

Abstract

This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches to optimise metabolic stability. Additionally, it presents different target structures and addresses corresponding tracers, which are already used in clinical routine or are being investigated in clinical trials.

Keywords: labelling strategies; metabolic stability; oncology; peptide receptor radiotherapy; positron emission tomography; radiolabelled peptides.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
[68Ga]Ga-OPS202 PET/CT [antagonist—(A,B)] and [68Ga]Ga-DOTATOC PET/CT [agonist—(C,D)] images of a patient with ileal neuroendocrine tumours , showing bilobar liver metastases (dashed lines indicate level of transaxial slices). Studies were performed on the same scanner within 2 months and show same gray (maximal-intensity projections, (A,C) and colour scale (transaxial fusion images, (B,D). Importantly, background activity was lower in liver, intestine, and thyroid with [68Ga]Ga-OPS202 than with [68Ga]Ga-DOTATOC allowing better identification of the lesions in the liver which are confirmed by subsequent MRI. (Adapted from Nicolas et al., originally puplished in J Nucl Med [142]).
Figure 2
Figure 2
(A) Structure of Glu-C(O)-Lys(Ahx-HBED-CC) (PSMA-11) for labelling with gallium-68 and PSMA-617 for labelling with, e.g., gallium-68 and lutetium-177. (B) 68Ga-PSMA-11 PET at baseline and (C) after 2 cycles of [177Lu]Lu-PSMA-617 therapy demonstrating considerable reduction of PSMA-expressing metastases in lymph nodes and bone (adapted from Fendler et al., originally published in J Nucl Med [183]).
Figure 3
Figure 3
PET images of some clinically studied RGD-based tracers 1 h after intravenous administration in healthy volunteers (B–D,F), a patient with melanoma (A), scrofula (E), lung cancer (G), and hepatocellular carcinoma (H). All images are coronal views. High tracer retention is notable in urogenital tract, due to predominant renal clearance. Intermediate uptake is found in the liver, spleen, and intestines. Reproduced with the permission from [5,45,47,190,207,208,209,210].
Figure 4
Figure 4
Structure of [68Ga]Ga-Pentixafor and PET MIP of a patient with multiple myeloma (modified from Wester et al., originally published in Theranostics [226]).
See this image and copyright information in PMC

References

    1. De Jong M., Bakker W.H., Krenning E.P., Breeman W.A., van der Pluijm M.E., Bernard B.F., Visser T.J., Jermann E., Behe M., Powell P., et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur. J. Nucl. Med. 1997;24:368–371. doi: 10.1007/BF00881807. - DOI - PubMed
    1. Henze M., Schuhmacher J., Hipp P., Kowalski J., Becker D.W., Doll J., Macke H.R., Hofmann M., Debus J., Haberkorn U. PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas. J. Nucl. Med. 2001;42:1053–1056. - PubMed
    1. Haubner R., Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front. Biosci. 2009;14:872–886. doi: 10.2741/3283. - DOI - PubMed
    1. Haubner R., Maschauer S., Prante O. PET radiopharmaceuticals for imaging integrin expression: Tracers in clinical studies and recent developments. BioMed Res. Int. 2014;2014:871609. doi: 10.1155/2014/871609. - DOI - PMC - PubMed
    1. Haubner R., Finkenstedt A., Stegmayr A., Rangger C., Decristoforo C., Zoller H., Virgolini I.J. [68Ga]NODAGA-RGD—Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. Eur. J. Nucl. Med. Mol. Imaging. 2016;43:2005–2013. doi: 10.1007/s00259-016-3396-3. - DOI - PMC - PubMed

LinkOut - more resources